{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:22:42Z","timestamp":1785900162911,"version":"3.56.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["5016-00168B"],"award-info":[{"award-number":["5016-00168B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10620-018-5395-7","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T08:33:21Z","timestamp":1543826001000},"page":"1238-1256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis"],"prefix":"10.1007","volume":"64","author":[{"given":"Kirstine S.","family":"T\u00f8lb\u00f8l","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Stierstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg F.","family":"Rippmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne S.","family":"Veidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer T. G.","family":"Rigbolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Sch\u00f6nberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Gillum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Jelsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Feigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4768-9074","authenticated-orcid":false,"given":"Andre","family":"Broermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"5395_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/liv.13299","volume":"37","author":"S Bellentani","year":"2017","unstructured":"Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37:81\u201384. \n                    https:\/\/doi.org\/10.1111\/liv.13299\n                    \n                  .","journal-title":"Liver Int"},{"key":"5395_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/bmb\/ldw031","volume":"119","author":"SA Townsend","year":"2016","unstructured":"Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull. 2016;119:143\u2013156. \n                    https:\/\/doi.org\/10.1093\/bmb\/ldw031\n                    \n                  .","journal-title":"Br Med Bull"},{"key":"5395_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2017","unstructured":"Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37:85\u201389. \n                    https:\/\/doi.org\/10.1111\/liv.13301\n                    \n                  .","journal-title":"Liver Int"},{"key":"5395_CR4","doi-asserted-by":"publisher","first-page":"389.e10","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389.e10\u2013397.e10. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2015.04.043\n                    \n                  .","journal-title":"Gastroenterology"},{"key":"5395_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","volume":"10","author":"GA Michelotti","year":"2013","unstructured":"Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656\u2013665. \n                    https:\/\/doi.org\/10.1038\/nrgastro.2013.183\n                    \n                  .","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5395_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/SLA.0b013e31826b4b7e","volume":"256","author":"VG Agopian","year":"2012","unstructured":"Agopian VG, Kaldas FM, Hong JC, et al. Liver transplantation for nonalcoholic steatohepatitis. Ann Surg. 2012;256:624\u2013633. \n                    https:\/\/doi.org\/10.1097\/SLA.0b013e31826b4b7e\n                    \n                  .","journal-title":"Ann Surg"},{"key":"5395_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrd.2015.3","volume":"15","author":"G Musso","year":"2016","unstructured":"Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249\u2013274. \n                    https:\/\/doi.org\/10.1038\/nrd.2015.3\n                    \n                  .","journal-title":"Nat Rev Drug Discov"},{"key":"5395_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.drudis.2015.10.015","volume":"21","author":"P Fagone","year":"2016","unstructured":"Fagone P, Mangano K, Pesce A, et al. Emerging therapeutic targets for the treatment of hepatic fibrosis. Drug Discov Today. 2016;21:369\u2013375. \n                    https:\/\/doi.org\/10.1016\/j.drudis.2015.10.015\n                    \n                  .","journal-title":"Drug Discov Today"},{"key":"5395_CR9","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","volume":"22","author":"HH Hansen","year":"2017","unstructured":"Hansen HH, Feigh M, Veidal SS, et al. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discov Today. 2017;22:1707\u20131718. \n                    https:\/\/doi.org\/10.1016\/j.drudis.2017.06.007\n                    \n                  .","journal-title":"Drug Discov Today"},{"key":"5395_CR10","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i16.673","author":"MNB Kristiansen","year":"2016","unstructured":"Kristiansen MNB, Veidal SS, Rigbolt KTG, et al. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol. 2016. \n                    https:\/\/doi.org\/10.4254\/wjh.v8.i16.673\n                    \n                  .","journal-title":"World J Hepatol"},{"key":"5395_CR11","doi-asserted-by":"publisher","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","volume":"305","author":"JR Clapper","year":"2013","unstructured":"Clapper JR, Hendricks MD, Gu G, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. AJP Gastrointest Liver Physiol. 2013;305:G483\u2013G495. \n                    https:\/\/doi.org\/10.1152\/ajpgi.00079.2013\n                    \n                  .","journal-title":"AJP Gastrointest Liver Physiol"},{"key":"5395_CR12","doi-asserted-by":"publisher","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","volume":"302","author":"JL Trevaskis","year":"2012","unstructured":"Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. AJP Gastrointest Liver Physiol. 2012;302:G762\u2013G772. \n                    https:\/\/doi.org\/10.1152\/ajpgi.00476.2011\n                    \n                  .","journal-title":"AJP Gastrointest Liver Physiol"},{"key":"5395_CR13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i2.179","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l KS, Kristiansen MNB, Hansen HH, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018. \n                    https:\/\/doi.org\/10.3748\/wjg.v24.i2.179\n                    \n                  .","journal-title":"World J Gastroenterol"},{"key":"5395_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","volume":"65","author":"A Asgharpour","year":"2016","unstructured":"Asgharpour A, Cazanave SC, Pacana T, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65:579\u2013588. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2016.05.005\n                    \n                  .","journal-title":"J Hepatol"},{"key":"5395_CR15","doi-asserted-by":"publisher","first-page":"G666","DOI":"10.1152\/ajpgi.00213.2016","volume":"312","author":"A Krishnan","year":"2017","unstructured":"Krishnan A, Abdullah TS, Mounajjed T, et al. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017;312:G666\u2013G680. \n                    https:\/\/doi.org\/10.1152\/ajpgi.00213.2016\n                    \n                  .","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"5395_CR16","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/hep.24737","volume":"55","author":"CL Roth","year":"2012","unstructured":"Roth CL, Elfers CT, Figlewicz DP, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology. 2012;55:1103\u20131111. \n                    https:\/\/doi.org\/10.1002\/hep.24737\n                    \n                  .","journal-title":"Hepatology"},{"key":"5395_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1053\/bega.2002.0332","volume":"16","author":"A Koteish","year":"2002","unstructured":"Koteish A, Mae Diehl A. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:679\u2013690.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"5395_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/cpmo.3","volume":"6","author":"A Jacobs","year":"2016","unstructured":"Jacobs A, Warda A-S, Verbeek J, et al. An overview of mouse models of nonalcoholic steatohepatitis: from past to present. Curr Protoc Mouse Biol. 2016;6:185\u2013200. \n                    https:\/\/doi.org\/10.1002\/cpmo.3\n                    \n                  .","journal-title":"Curr Protoc Mouse Biol"},{"key":"5395_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00535-012-0651-7","volume":"48","author":"Y Tamaki","year":"2013","unstructured":"Tamaki Y, Nakade Y, Yamauchi T, et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491\u2013503. \n                    https:\/\/doi.org\/10.1007\/s00535-012-0651-7\n                    \n                  .","journal-title":"J Gastroenterol"},{"key":"5395_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94:93\u2013103. \n                    https:\/\/doi.org\/10.1111\/iep.12008\n                    \n                  .","journal-title":"Int J Exp Pathol"},{"key":"5395_CR21","doi-asserted-by":"publisher","first-page":"e97136","DOI":"10.1371\/journal.pone.0097136","volume":"9","author":"S Minicis De","year":"2014","unstructured":"De Minicis S, Agostinelli L, Rychlicki C, et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS ONE. 2014;9:e97136. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0097136\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"5395_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","volume":"754","author":"Y Hayashizaki-Someya","year":"2015","unstructured":"Hayashizaki-Someya Y, Kurosaki E, Takasu T, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;754:19\u201324. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.009\n                    \n                  .","journal-title":"Eur J Pharmacol"},{"key":"5395_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","volume":"315","author":"K Kawaguchi","year":"2004","unstructured":"Kawaguchi K, Sakaida I, Tsuchiya M, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet. Biochem Biophys Res Commun. 2004;315:187\u2013195. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2004.01.038\n                    \n                  .","journal-title":"Biochem Biophys Res Commun"},{"key":"5395_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/hep4.1104","volume":"1","author":"T Namisaki","year":"2017","unstructured":"Namisaki T, Moriya K, Kitade M, et al. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. Hepatol Commun. 2017;1:928\u2013945. \n                    https:\/\/doi.org\/10.1002\/hep4.1104\n                    \n                  .","journal-title":"Hepatol Commun"},{"key":"5395_CR25","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00535-013-0906-y","volume":"49","author":"H Yoshiji","year":"2014","unstructured":"Yoshiji H, Noguchi R, Namisaki T, et al. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol. 2014;49:1421\u20131429. \n                    https:\/\/doi.org\/10.1007\/s00535-013-0906-y\n                    \n                  .","journal-title":"J Gastroenterol"},{"key":"5395_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/hepr.12081","volume":"43","author":"Y Aihara","year":"2013","unstructured":"Aihara Y, Yoshiji H, Noguchi R, et al. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res. 2013;43:1241\u20131250. \n                    https:\/\/doi.org\/10.1111\/hepr.12081\n                    \n                  .","journal-title":"Hepatol Res"},{"key":"5395_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hepres.2005.05.008","volume":"32","author":"H Uto","year":"2005","unstructured":"Uto H, Nakanishi C, Ido A, et al. The peroxisome proliferator-activated receptor-\u03b3 agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, -amino acid-defined diet. Hepatol Res. 2005;32:235\u2013242. \n                    https:\/\/doi.org\/10.1016\/j.hepres.2005.05.008\n                    \n                  .","journal-title":"Hepatol Res"},{"key":"5395_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280\u2013295. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2017.11.014\n                    \n                  .","journal-title":"J Hepatol"},{"key":"5395_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","volume":"27","author":"GN Ioannou","year":"2016","unstructured":"Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab. 2016;27:84\u201395. \n                    https:\/\/doi.org\/10.1016\/j.tem.2015.11.008\n                    \n                  .","journal-title":"Trends Endocrinol Metab"},{"key":"5395_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u2013965. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4\n                    \n                  .","journal-title":"Lancet"},{"key":"5395_CR31","doi-asserted-by":"publisher","first-page":"1147\u20131159e5","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147\u20131159e5. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2016.01.038\n                    \n                  .","journal-title":"Gastroenterology"},{"key":"5395_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12072-015-9656-7","volume":"9","author":"A Asgharpour","year":"2015","unstructured":"Asgharpour A, Kumar D, Sanyal A. Bile acids: emerging role in management of liver diseases. Hepatol Int. 2015;9:527\u2013533. \n                    https:\/\/doi.org\/10.1007\/s12072-015-9656-7\n                    \n                  .","journal-title":"Hepatol Int"},{"key":"5395_CR33","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569\u20133572.","journal-title":"J Med Chem"},{"key":"5395_CR34","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs. 2016;76:1221\u20131226. \n                    https:\/\/doi.org\/10.1007\/s40265-016-0616-x\n                    \n                  .","journal-title":"Drugs"},{"key":"5395_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s40495-017-0085-2","volume":"3","author":"LE Armstrong","year":"2017","unstructured":"Armstrong LE, Guo GL. Role of FXR in liver inflammation during nonalcoholic steatohepatitis. Curr Pharmacol Rep. 2017;3:92\u2013100. \n                    https:\/\/doi.org\/10.1007\/s40495-017-0085-2\n                    \n                  .","journal-title":"Curr Pharmacol Rep"},{"key":"5395_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/oby.21701","volume":"25","author":"F Haczeyni","year":"2017","unstructured":"Haczeyni F, Poekes L, Wang H, et al. Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity (Silver Spring). 2017;25:155\u2013165. \n                    https:\/\/doi.org\/10.1002\/oby.21701\n                    \n                  .","journal-title":"Obesity (Silver Spring)"},{"key":"5395_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","volume":"24","author":"JD Roth","year":"2018","unstructured":"Roth JD, Feigh M, Veidal SS, et al. INT-767 improves histopathological features in a diet-inducedob\/obmouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol. 2018;24:195\u2013210. \n                    https:\/\/doi.org\/10.3748\/wjg.v24.i2.195\n                    \n                  .","journal-title":"World J Gastroenterol"},{"key":"5395_CR38","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","volume":"6","author":"H Jouihan","year":"2017","unstructured":"Jouihan H, Will S, Guionaud S, et al. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Mol Metab. 2017;6:1360\u20131370. \n                    https:\/\/doi.org\/10.1016\/j.molmet.2017.09.001\n                    \n                  .","journal-title":"Mol Metab"},{"key":"5395_CR39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2017","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2017;62:720\u2013733. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2014.10.039\n                    \n                  .","journal-title":"J Hepatol"},{"key":"5395_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.05.011","author":"N Tanaka","year":"2017","unstructured":"Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol Ther. 2017. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2017.05.011\n                    \n                  .","journal-title":"Pharmacol Ther"},{"key":"5395_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bph.14118","volume":"31","author":"M Baader","year":"2017","unstructured":"Baader M, Bretschneider T, Broermann A, et al. Characterisation of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis. Br J Pharmacol. 2017;31:693\u2013707. \n                    https:\/\/doi.org\/10.1111\/bph.14118\n                    \n                  .","journal-title":"Br J Pharmacol"},{"key":"5395_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u20131321. \n                    https:\/\/doi.org\/10.1002\/hep.20701\n                    \n                  .","journal-title":"Hepatology"},{"key":"5395_CR43","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/gut.2007.144550","volume":"57","author":"K Fujita","year":"2008","unstructured":"Fujita K, Nozaki Y, Wada K, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008;57:1583\u20131591. \n                    https:\/\/doi.org\/10.1136\/gut.2007.144550\n                    \n                  .","journal-title":"Gut"},{"key":"5395_CR44","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/db06-0097","volume":"55","author":"PJ Raubenheimer","year":"2006","unstructured":"Raubenheimer PJ, Nyirenda MJ, Walker BR. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes. 2006;55:2015\u20132020. \n                    https:\/\/doi.org\/10.2337\/db06-0097\n                    \n                  .","journal-title":"Diabetes"},{"key":"5395_CR45","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1194\/jlr.M800042-JLR200","volume":"49","author":"ME Rinella","year":"2008","unstructured":"Rinella ME, Elias MS, Smolak RR, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008;49:1068\u20131076. \n                    https:\/\/doi.org\/10.1194\/jlr.M800042-JLR200\n                    \n                  .","journal-title":"J Lipid Res"},{"key":"5395_CR46","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1139\/o85-108","volume":"63","author":"JE Vance","year":"1985","unstructured":"Vance JE, Vance DE. The role of phosphatidylcholine biosynthesis in the secretion of lipoproteins from hepatocytes. Can J Biochem Cell Biol. 1985;63:870\u2013881. \n                    https:\/\/doi.org\/10.1139\/o85-108\n                    \n                  .","journal-title":"Can J Biochem Cell Biol"},{"key":"5395_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/molmed.2016.00203","volume":"23","author":"J Henkel","year":"2017","unstructured":"Henkel J, Coleman CD, Schraplau A, et al. Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol. Mol Med. 2017;23:1. \n                    https:\/\/doi.org\/10.2119\/molmed.2016.00203\n                    \n                  .","journal-title":"Mol Med"},{"key":"5395_CR48","doi-asserted-by":"publisher","first-page":"e84221","DOI":"10.1371\/journal.pone.0084221","volume":"9","author":"K Ma","year":"2014","unstructured":"Ma K, Malhotra P, Soni V, et al. Overactivation of intestinal SREBP2 in mice increases serum cholesterol. PLoS ONE. 2014;9:e84221. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0084221\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"5395_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0005-2760(79)90067-5","volume":"573","author":"S Robins","year":"1979","unstructured":"Robins S, Russo A. Regulation of body cholesterol pools. Influence of cholesterol input and excretion in an animal model. Biochim Biophys Acta. 1979;573:343\u2013353.","journal-title":"Biochim Biophys Acta"},{"key":"5395_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/019262339502300504","volume":"23","author":"D Nakae","year":"1995","unstructured":"Nakae D, Mizumoto Y, Andoh N, et al. Comparative changes in the liver of female fischer-344 rats after short-term feeding of a semipurified or a semisynthetic l-amino acid-defined choline-deficient diet. Toxicol Pathol. 1995;23:583\u2013590. \n                    https:\/\/doi.org\/10.1177\/019262339502300504\n                    \n                  .","journal-title":"Toxicol Pathol"},{"key":"5395_CR51","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VW-S, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Prim. 2015;1:15080. \n                    https:\/\/doi.org\/10.1038\/nrdp.2015.80\n                    \n                  .","journal-title":"Nat Rev Dis Prim"},{"key":"5395_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1586\/egh.11.8","volume":"5","author":"C Lackner","year":"2011","unstructured":"Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist\u2019s perspective. Expert Rev Gastroenterol Hepatol. 2011;5:223\u2013231. \n                    https:\/\/doi.org\/10.1586\/egh.11.8\n                    \n                  .","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"5395_CR53","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1046\/j.1440-1827.1999.00990.x","volume":"49","author":"D Nakae","year":"1999","unstructured":"Nakae D. Endogenous liver carcinogenesis in the rat. Pathol Int. 1999;49:1028\u20131042.","journal-title":"Pathol Int"},{"key":"5395_CR54","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","volume":"92","author":"A Wree","year":"2014","unstructured":"Wree A, McGeough MD, Pe\u00f1a CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med. 2014;92:1069\u20131082. \n                    https:\/\/doi.org\/10.1007\/s00109-014-1170-1\n                    \n                  .","journal-title":"J Mol Med"},{"key":"5395_CR55","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.3748\/wjg.14.6655","volume":"14","author":"H Kawaratani","year":"2008","unstructured":"Kawaratani H, Tsujimoto T, Kitazawa T, et al. Innate immune reactivity of the liver in rats fed a choline-deficient l-amino-acid-defined diet. World J Gastroenterol. 2008;14:6655\u20136661. \n                    https:\/\/doi.org\/10.3748\/wjg.14.6655\n                    \n                  .","journal-title":"World J Gastroenterol"},{"key":"5395_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/carcin\/23.2.245","volume":"23","author":"A Denda","year":"2002","unstructured":"Denda A, Kitayama W, Murata A, et al. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, l-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis. 2002;23:245\u2013256.","journal-title":"Carcinogenesis"},{"key":"5395_CR57","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/hepr.12709","volume":"47","author":"Y Amano","year":"2017","unstructured":"Amano Y, Shimizu F, Yasuno H, et al. Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Hepatol Res. 2017;47:103\u2013115. \n                    https:\/\/doi.org\/10.1111\/hepr.12709\n                    \n                  .","journal-title":"Hepatol Res"},{"key":"5395_CR58","doi-asserted-by":"publisher","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","volume":"302","author":"K Miura","year":"2012","unstructured":"Miura K, Yang L, van Rooijen N, et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Liver Physiol. 2012;302:G1310\u2013G1321. \n                    https:\/\/doi.org\/10.1152\/ajpgi.00365.2011\n                    \n                  .","journal-title":"Am J Physiol Liver Physiol"},{"key":"5395_CR59","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.3748\/wjg.15.5533","volume":"15","author":"T Tsujimoto","year":"2009","unstructured":"Tsujimoto T, Kawaratani H, Kitazawa T, et al. Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138. World J Gastroenterol. 2009;15:5533\u20135540.","journal-title":"World J Gastroenterol"},{"key":"5395_CR60","doi-asserted-by":"publisher","first-page":"323.e7","DOI":"10.1053\/j.gastro.2010.03.052","volume":"139","author":"K Miura","year":"2010","unstructured":"Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1\u03b2 in mice. Gastroenterology. 2010;139:323.e7\u2013334.e7. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2010.03.052\n                    \n                  .","journal-title":"Gastroenterology"},{"key":"5395_CR61","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2009.03.008","volume":"51","author":"G Baffy","year":"2009","unstructured":"Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51:212\u2013223. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2009.03.008\n                    \n                  .","journal-title":"J Hepatol"},{"key":"5395_CR62","doi-asserted-by":"publisher","first-page":"e0159524","DOI":"10.1371\/journal.pone.0159524","volume":"11","author":"DT Reid","year":"2016","unstructured":"Reid DT, Reyes JL, McDonald BA, et al. Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation. PLoS ONE. 2016;11:e0159524. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0159524\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"5395_CR63","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.26937","volume":"59","author":"VL Gadd","year":"2014","unstructured":"Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393\u20131405. \n                    https:\/\/doi.org\/10.1002\/hep.26937\n                    \n                  .","journal-title":"Hepatology"},{"key":"5395_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/liv.13653","volume":"38","author":"P Bedossa","year":"2018","unstructured":"Bedossa P. Diagnosis of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: why liver biopsy is essential. Liver Int. 2018;38:64\u201366. \n                    https:\/\/doi.org\/10.1111\/liv.13653\n                    \n                  .","journal-title":"Liver Int"},{"key":"5395_CR65","doi-asserted-by":"publisher","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","volume":"9","author":"W Liang","year":"2014","unstructured":"Liang W, Menke AL, Driessen A, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS ONE. 2014;9:e115922. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0115922\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"5395_CR66","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/iep.12240","volume":"98","author":"A Ikawa-Yoshida","year":"2017","unstructured":"Ikawa-Yoshida A, Matsuo S, Kato A, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, l-amino acid-defined, high-fat diet. Int J Exp Pathol. 2017;98:221\u2013233. \n                    https:\/\/doi.org\/10.1111\/iep.12240\n                    \n                  .","journal-title":"Int J Exp Pathol"},{"key":"5395_CR67","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/hep.26461","volume":"58","author":"B Staels","year":"2013","unstructured":"Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology. 2013;58:1941\u20131952. \n                    https:\/\/doi.org\/10.1002\/hep.26461\n                    \n                  .","journal-title":"Hepatology"},{"key":"5395_CR68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tox.2007.09.030","volume":"246","author":"FJ Gonzalez","year":"2008","unstructured":"Gonzalez FJ, Shah YM. PPAR\u03b1: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology. 2008;246:2\u20138. \n                    https:\/\/doi.org\/10.1016\/j.tox.2007.09.030\n                    \n                  .","journal-title":"Toxicology"},{"key":"5395_CR69","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","volume":"1821","author":"A Tailleux","year":"2012","unstructured":"Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta Mol Cell Biol Lipids. 2012;1821:809\u2013818. \n                    https:\/\/doi.org\/10.1016\/j.bbalip.2011.10.016\n                    \n                  .","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"5395_CR70","doi-asserted-by":"publisher","first-page":"G283","DOI":"10.1152\/ajpgi.00205.2016","volume":"312","author":"CN Brocker","year":"2017","unstructured":"Brocker CN, Yue J, Kim D, et al. Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells. Am J Physiol Liver Physiol. 2017;312:G283\u2013G299. \n                    https:\/\/doi.org\/10.1152\/ajpgi.00205.2016\n                    \n                  .","journal-title":"Am J Physiol Liver Physiol"},{"key":"5395_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13634","author":"MR Jain","year":"2017","unstructured":"Jain MR, Giri SR, Bhoi B, et al. Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2017. \n                    https:\/\/doi.org\/10.1111\/liv.13634\n                    \n                  .","journal-title":"Liver Int"},{"key":"5395_CR72","doi-asserted-by":"publisher","first-page":"46273","DOI":"10.18632\/oncotarget.17695","volume":"8","author":"SM Kim","year":"2017","unstructured":"Kim SM, Lee B, An HJ, et al. Novel PPAR\u03b1 agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. Oncotarget. 2017;8:46273\u201346285. \n                    https:\/\/doi.org\/10.18632\/oncotarget.17695\n                    \n                  .","journal-title":"Oncotarget"},{"key":"5395_CR73","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12864-015-1969-3","volume":"16","author":"AWF Janssen","year":"2015","unstructured":"Janssen AWF, Betzel B, Stoopen G, et al. The impact of PPAR\u03b1 activation on whole genome gene expression in human precision cut liver slices. BMC Genom. 2015;16:760. \n                    https:\/\/doi.org\/10.1186\/s12864-015-1969-3\n                    \n                  .","journal-title":"BMC Genom"},{"key":"5395_CR74","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/hep4.1072","volume":"1","author":"F Haczeyni","year":"2017","unstructured":"Haczeyni F, Wang H, Barn V, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017;1:663\u2013674. \n                    https:\/\/doi.org\/10.1002\/hep4.1072\n                    \n                  .","journal-title":"Hepatol Commun"},{"key":"5395_CR75","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.3748\/wjg.v21.i45.12787","volume":"21","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, Yeon JE, Ko EJ, et al. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21:12787. \n                    https:\/\/doi.org\/10.3748\/wjg.v21.i45.12787\n                    \n                  .","journal-title":"World J Gastroenterol"},{"key":"5395_CR76","doi-asserted-by":"publisher","first-page":"44612","DOI":"10.1038\/srep44612","volume":"7","author":"W Luo","year":"2017","unstructured":"Luo W, Xu Q, Wang Q, et al. Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep. 2017;7:44612. \n                    https:\/\/doi.org\/10.1038\/srep44612\n                    \n                  .","journal-title":"Sci Rep"},{"key":"5395_CR77","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1111\/j.1476-5381.2010.00671.x","volume":"160","author":"M Collino","year":"2010","unstructured":"Collino M, Aragno M, Castiglia S, et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol. 2010;160:1892\u20131902. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00671.x\n                    \n                  .","journal-title":"Br J Pharmacol"},{"key":"5395_CR78","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","volume":"51","author":"S Zhang","year":"2009","unstructured":"Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380\u2013388. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2009.03.025\n                    \n                  .","journal-title":"J Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5395-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5395-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5395-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:15:25Z","timestamp":1575314125000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5395-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["5395"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5395-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KST, SSV, KGTR, HHH, NV, JJ, and MF are full-time employees at Gubra Aps. BS, JFR, TS, and AB are full-time employees at Boehringer-Ingelheim Pharma GmbH & Co. KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}